Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04534153 · ClinicalTrials.gov registry record · Early Phase 1
Excipient Effect on Drug Absorption in Humans
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT04534153 is a Early Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 12 participants.
The verdict
NCT04534153, a Early Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if sodium lauryl sulfate (SLS), a non-drug ingredient commonly added in drug products, affect absorption of drugs that are given together with the ingredient. Investigators want to find out if drug absorption is different in people taking the drug alone compared to people taking the drug with low and high amounts of sodium lauryl sulfate at the same time.
Interventions
- DRUG Fexofenadine Hydrochloride without sodium lauryl sulfate
- DRUG Fexofenadine Hydrochloride with sodium lauryl sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2025-08-18 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04534153
The ClinicalTrials.gov registry entry for NCT04534153 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fexofenadine Hydrochloride without sodium lauryl sulfate is the first listed.
NCT04534153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04534153 about?
NCT04534153 is a clinical study titled "Excipient Effect on Drug Absorption in Humans". The purpose of this study is to determine if sodium lauryl sulfate (SLS), a non-drug ingredient commonly added in drug products, affect absorption of drugs that are given together with the ingredient. Investigators want to find out if drug absorption is different in people taking the drug alone comp...
What is the current status of trial NCT04534153?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2023-01-31. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT04534153?
The interventions under investigation include: Fexofenadine Hydrochloride without sodium lauryl sulfate (DRUG), Fexofenadine Hydrochloride with sodium lauryl sulfate (DRUG).
Who is sponsoring clinical trial NCT04534153?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.